Abstract
Patients using direct oral anticoagulants (DOACs) are a growing number. These anticoagulant treatments especially during hospitalization can be challenging not only in their management but also in assessing biological tests results, particularly hemostasis tests. When stopping DOACs, tests interpretation is all the more complex since the molecule has residual activity that could interfere with coagulation tests. Apixaban is a direct factor Xa inhibitor that interferes in heparin dosage, as well as rivaroxaban, and continues to do so two days after therapy is interrupted (or more if kidney failure). This heparin “overdosage” must not be considered for heparin dose adaptation. Medical biologists have to be aware of this interference in order to warn physicians.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
